DUOPHARMA BIOTECH BERHAD

KLSE (MYR): DPHARMA (7148)

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

1.21

Today's Change

0.00 (0.00%)

Day's Change

1.21 - 1.23

Trading Volume

356,200

Financial
Market Cap

Market Cap

1,164 Million

NOSH

962 Million

Latest Quarter

Latest Quarter

31-Dec-2023 [#4]

Announcement Date

22-Feb-2024

Next Quarter

31-Mar-2024

Est. Ann. Date

22-May-2024

Est. Ann. Due Date

30-May-2024

QoQ | YoY

-5.22% | -50.46%

T4Q Result

Revenue | NP to SH

704,727.000 | 52,646.000

RPS | P/RPS

73.26 Cent | 1.65

EPS | P/E | EY

5.47 Cent | 22.11 | 4.52%

DPS | DY | Payout %

2.30 Cent | 1.90% | 41.99%

NAPS | P/NAPS

0.71 | 1.70

QoQ | YoY

-14.12% | -24.91%

NP Margin | ROE

7.47% | 7.71%

F.Y. | Ann. Date

31-Dec-2023 | 22-Feb-2024

Latest Audited Result

Latest Audited Result

31-Dec-2023

Announcement Date

26-Apr-2024

Next Audited Result

31-Dec-2024

Est. Ann. Date

26-Apr-2025

Est. Ann. Due Date

29-Jun-2025

Annual (Unaudited)

Revenue | NP to SH

704,727.000 | 52,645.000

RPS | P/RPS

73.26 Cent | 1.65

EPS | P/E | EY

5.49 Cent | 22.11 | 4.52%

DPS | DY | Payout %

2.30 Cent | 1.90% | 42.03%

NAPS | P/NAPS

0.71 | 1.70

YoY

-24.91%

NP Margin | ROE

7.47% | 7.71%

F.Y. | Ann. Date

31-Dec-2023 | 22-Feb-2024

Annualized Result

Revenue | NP to SH

704,727.000 | 52,645.000

RPS | P/RPS

73.26 Cent | 1.65

EPS | P/E | EY

5.49 Cent | 22.11 | 4.52%

DPS | DY | Payout %

-

NAPS | P/NAPS

-

QoQ | YoY

-10.55% | -24.91%

NP Margin | ROE

7.47% | 7.71%

F.Y. | Ann. Date

31-Dec-2023 | 22-Feb-2024

Business Process

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 0 / 4 0.00% 0 / 8 0.00%
Total Positive Profit Years 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Positive Profit 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Profit Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted EPS Growth 0 / 4 0.00% 0 / 8 0.00%
Total Dividend Years 2 / 4 50.00% 4 / 8 50.00%
Continuous Quarters Of Dividend 1 / 4 25.00% 1 / 8 12.50%
Continuous Quarters Of Dividend Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted Dps Growth 1 / 4 25.00% 1 / 8 12.50%
Average ROE 1.96% 2.35%
Average Net Profit Margin 7.29% 8.70%

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Quarters Of Revenue Growth 3 / 5 60.00% 3 / 10 30.00%
Total Positive Profit Years 5 / 5 100.00% 10 / 10 100.00%
Continuous Quarters Of Positive Profit 5 / 5 100.00% 10 / 10 100.00%
Continuous Quarters Of Profit Growth 0 / 5 0.00% 0 / 10 0.00%
Continuous Quarters Of Adjusted EPS Growth 0 / 5 0.00% 0 / 10 0.00%
Total Dividend Years 5 / 5 100.00% 10 / 10 100.00%
Continuous Quarters Of Dividend 5 / 5 100.00% 10 / 10 100.00%
Continuous Quarters Of Dividend Growth 2 / 5 40.00% 2 / 10 20.00%
Continuous Quarters Of Adjusted Dps Growth 2 / 5 40.00% 2 / 10 20.00%
Average ROE 9.72% 10.59%
Average Net Profit Margin 9.54% 11.95%
Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 704,727 704,727 704,727 491,427 637,396
NP to SH 52,646 52,645 52,645 49,361 60,464
Dividend 22,103 22,124 22,124 27,228 30,503
Adjusted EPS 5.47 5.49 5.49 5.13 6.29
Adjusted DPS 2.30 2.30 2.30 2.83 3.17

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.

Growth

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue -1.02% 10.23% 1.15% -4.93% -4.38%
NP to Owner -5.22% -50.46% -24.91% -35.40% -44.59%
Dividend 0.00% 1.02% 1.02% 213.34% 214.97%
Adjusted EPS -5.38% -50.67% -24.68% -35.61% -44.81%
Adjusted DPS 0.00% 1.02% 1.02% 213.34% 214.97%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue 0.00% 10.56% 43.40% 0.00% 10.56% 43.40% 1.15% 10.56% 43.40%
NP to Owner 0.00% -12.93% 6.65% 0.00% -12.93% 6.65% -24.91% -12.93% 6.65%
Dividend -0.09% -27.54% -18.82% 0.00% -27.47% -18.74% 1.02% -27.47% -18.74%
Adjusted EPS -0.36% -13.02% 6.56% 0.00% -12.71% 6.95% -24.68% -12.71% 6.95%
Adjusted DPS 0.00% -27.47% -18.74% 0.00% -27.47% -18.74% 1.02% -27.47% -18.74%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Discussions
13 people like this. Showing 50 of 12,436 comments

Bon888

Post removed.Why?

2023-05-23 08:04

Bon888

Post removed.Why?

2023-05-23 09:16

Bon888

Got 21mil profit but share price not moving. Volume so low.

No sesy sesy stories share price how to fly? Last time got vaccine story. Now?

2023-05-23 13:49

Bon888

Post removed.Why?

2023-05-29 12:19

James Ng

[转贴] [Video:浅谈DUOPHARMA BIOTECH BERHAD, DPHARMA, 7148] - James的股票投资James Share Investing
https://klse.i3investor.com/web/blog/detail/general/2023-08-12-story-h-242875199

2023-08-12 21:08

fortunefire

got my attention. see if it can drop below 1.2

2023-08-15 09:58

NoTimeToTrade

1.26 is immediate resistance, if break then need to buy

2023-08-15 11:35

midswing

Down the hill...
Potential rebound?

2023-08-18 23:17

chkhooju

Possible.

2023-08-24 13:39

NoTimeToTrade

Quarter results already reflected in the price before the release of the Q2 report

2023-08-25 11:37

fortunefire

good company, can buy more?

2023-08-28 15:00

100Mark

Still a profit-making company. IF got free cash, may be can chip in some

2023-09-04 10:54

100Mark

reaching 52 weeks low, time to grab a bit

2023-09-06 10:28

stevenckheng

noob company slowly moving a way from pharmaceutical

2023-09-06 20:25

teknikal

Support at RM1.10, if broken then RM1 is the next support

2023-09-11 09:17

fortunefire

parking here. tp 0.9x

2023-09-11 11:08

chkhooju

Moving up nicely.

2023-09-11 12:51

BobAxelrod33

Managed and operated by white haired people sitting in wheel chairs and using walking sticks. Most have prostate problems, waking few times at night to urinate. Some are waiting for stairways to Heavens........HOW COULD COMPANY BE AGGRESSIVE???

2023-10-08 13:10

MrFox

fruitcake becimes mouldy!!

2023-11-09 11:38

MagicalBobby

3Q23 profits down 45% YoY....current BOD is a team of silver haired centennials in wheelchairs. Raising 2 Billion bonds for retirement benefits?

BOD too aggressive is bad, weak BOD is also bad.......take your pick.

2023-11-10 12:07

Apastock

mari mari 1.50 yihaa ....

2023-11-10 12:55

BobAxelrod6868

You'd be lucky to even break 1.40.......

2023-11-21 07:47

BobAxelrod33

Pharma is dying, yet this ctnr with Management in wheelchairs cannot take advantage.

2023-12-02 09:04

BobAxelrod33

Max speed 2 mph......take your pick.

2023-12-04 15:13

Jettson8

not yet, it will make good performance in Q4

2023-12-06 16:38

Jettson8

it starts rebounding 😀 up up up

2023-12-15 15:38

NoTimeToTrade

This is just reaction to Covid case spike, after that fall back down. Nothing new and exciting on the horizon for pharma in the coming months especially when Pharmaniaga still in the dump and government cutting back on spending.

2023-12-15 16:03

Liner8

Great upup

2023-12-16 06:54

143922

3.00 is coming

2023-12-16 12:49

Jettson8

Dpharma is more stable and solid than those companies, fruitcake

2023-12-24 09:46

143922

Jual je la sykt GLC ni.epf pun tak mau beli ticket.kannaya

2023-12-31 09:31

Jettson8

Hope this collaboration can bring good revenue to the company for Fy2024 and so on

https://theedgemalaysia.com/node/692365

2024-01-15 17:14

100Mark

See, Kwsp was buying in. I think it can 😄

2024-01-22 17:34

Jettson8

Ya, even TA securities raised its target price to Rm1.47

2024-01-26 15:41

100Mark

Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.

https://www.thestar.com.my/business/business-news/2024/01/26/duopharma-earnings-set-to-improve-this-year

2024-01-30 17:36

metaverse

This is my trading call dated 15 Dec 2020. Most of the time chart will tell the true story:

https://www.tradingview.com/chart/DPHARMA/5tKe08jN-Trend-Analysis/


For investment or trading ideas, please feel free to visit my chart gallery:

https://www.tradingview.com/u/Yang358/#published-charts

2024-01-31 17:43

100Mark

@metaverse. What did you use for that technical analysis?

2024-02-02 16:19

metaverse

I love astronomy so most of my calculation/logics actually somehow related to astrophysics and planetary orbit. Something to do with price resistance, time resistance and speed resistance.

2024-02-02 16:45

MrFox

fruitcake turns mouldy?

2 months ago

Meshach Mano

Starting its journey to 1.4 soon

1 week ago

cyberzigot

Limit up

6 days ago

Mar2083

Afternoon sessions limit up
Huat ar

6 days ago

NoTimeToTrade

Duopharma Biotech Clinches MYR578 million Supply Deals

https://www.tradingview.com/news/mtnewswires.com:20240501:G2361746:0/

6 days ago

jenabchen123

Yuhoo!!! Finally Duo making big move. 1.40 seems reasonable figure to relief breath.

6 days ago

Mar2083

Potentially may test 1. 4 tomorrow

6 days ago

fruitcake

today....masuk longkang 😂

5 days ago

jenabchen123

Ayo!!! What has 600m contract do to the Duo's share price??? Sometime the illogical happen.....

4 days ago

fruitcake

derailed

2 days ago

fruitcake

ubat racun contract 😂😂🤣

2 days ago

fruitcake

next 2 days lagi best. 6 mil vol due. manis

2 days ago

Post a Comment